Certara, Inc. (NASDAQ:CERT) Stock Has Consensus Price Target of $8.28

Key Points

• Analyst sentiment is neutral: Certara has a consensus “Hold” rating from 11 analysts, with an average 12-month price target of $8.28.
• Recent results fell short of expectations: The company reported quarterly EPS of $0.08 versus the $0.09 consensus estimate and revenue of $93.27 million versus expectations of $98.09 million; revenue declined 10.8% year over year.
• Institutional ownership remains high: Hedge funds and other institutional investors hold approximately 73.96% of Certara’s outstanding shares, while several firms recently increased their positions.

Certara, Inc. (NASDAQ:CERT - Get Free Report) has been assigned an average recommendation of "Hold" from the eleven ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $8.28.

CERT has been the topic of a number of recent analyst reports. Barclays increased their price objective on Certara from $6.50 to $7.50 and gave the stock an "equal weight" rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded Certara from a "sell (e+)" rating to a "sell (d)" rating in a research report on Wednesday, August 5th.

Certara Price Performance

Shares of NASDAQ:CERT opened at $8.89 on Friday. The company has a 50 day moving average of $8.01 and a 200 day moving average of $6.65. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The stock has a market cap of $1.36 billion, a P/E ratio of -19.76 and a beta of 1.40. Certara has a 12 month low of $4.45 and a 12 month high of $13.88.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $93.27 million during the quarter, compared to analysts' expectations of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.07 earnings per share. As a group, sell-side analysts forecast that Certara will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Certara

A number of large investors have recently added to or reduced their stakes in CERT. Sequoia Financial Advisors LLC raised its holdings in shares of Certara by 12.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company's stock valued at $117,000 after buying an additional 1,923 shares in the last quarter. NorthRock Partners LLC purchased a new stake in Certara during the 2nd quarter valued at $68,000. Integrated Wealth Concepts LLC bought a new position in shares of Certara during the second quarter valued at about $39,000. Corient Private Wealth LP raised its position in Certara by 166.8% during the 2nd quarter. Corient Private Wealth LP now owns 74,316 shares of the company's stock valued at $487,000 after purchasing an additional 46,462 shares during the last quarter. Finally, Amundi lifted its stake in Certara by 76.0% in the second quarter. Amundi now owns 44,586 shares of the company's stock worth $292,000 after acquiring an additional 19,250 shares during the period. Hedge funds and other institutional investors own 73.96% of the company's stock.

About Certara

Certara NASDAQ: CERT provides software and technology-enabled services that support the development, approval and commercialization of medicines. The company specializes in model-informed drug development, using pharmacometrics, simulation, data analysis and regulatory science to help biopharmaceutical companies evaluate drug safety, efficacy, dosing and potential regulatory outcomes.

Its software portfolio includes platforms such as Simcyp, which supports clinical pharmacology and drug-interaction modeling; Phoenix, used for pharmacokinetic and pharmacodynamic analysis; and Pinnacle 21, which helps organizations manage clinical data standards and regulatory submissions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.